Ivabradine Viatris

Ivabradine, the active ingredient in Ivabradine Viatris, is an If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is used in patients with chronic stable angina pectoris and in certain heart‑failure patients. GNH USA supplies Ivabradine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to reduce heart rate in several cardiovascular conditions. - Chronic stable angina pectoris: decreases frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction (NYHA class II–III): improves symptoms and may reduce hospitalisation by reducing heart rate. - Patients intolerant to beta‑blockers: provides an alternative mechanism for heart‑rate control.

Common Side Effects: - Visual disturbances (phosphenes or luminous phenomena) - Bradycardia (slow heart rate) - Headache - Dizziness - Fatigue - Blurred vision

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention - Atrial fibrillation or other arrhythmias - Severe hypotension - Persistent visual impairment - Heart block or conduction abnormalities - Severe allergic reactions (anaphylaxis).

Before initiating therapy, assess baseline heart rate and cardiac function. - Monitor heart rate: ensure resting rate is ≥60 bpm before starting. - Avoid in severe hepatic impairment: dose adjustment may be required. - Use caution in patients with sick sinus syndrome or atrioventricular block. - Avoid concomitant strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin). - Store at below 25°C: keep in the original pack, protect from moisture.

Ivabradine may interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole) – may increase plasma levels. - Other heart‑rate lowering agents (beta‑blockers, digoxin, diltiazem, verapamil) – risk of excessive bradycardia. - Certain anti‑arrhythmic drugs (e.g., amiodarone) – may potentiate conduction effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) – may reduce efficacy. - Antihypertensive agents (ACE inhibitors, ARBs) – monitor blood pressure. - Diuretics – watch for electrolyte disturbances that could affect cardiac rhythm.